London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Crazy... 46% down on the opening. 38m market cap. Who is going to sell at these levels. Rather hold it privately if possible
Not totally sure, as normally you would expect some sort of approach to be announced. I've been in a similar situation about three times when Private Equity buyer comes along, but usually there is an offer on the table. Unless the company has made some sort of secret agreement with a private buyer agreeing to sell out on the cheap, but not sure institutional investors would go with that, unless one of them is behind it?
Somewhat ironic. I have large holding here. I chose cause I really thought this was a quality biotech play on AIM, rather than one of more sketchy ones. Obviously short term hit to share price/value, but not sure on long term horizon. As their quality here. So I'm thinking I should get a lot more than this current price further down the line....
Do you thunk they'll make a move and what process moniman please
When is the jazz money due
Thanks
L
That would make sense. They want to be bought by private equity company. But what will be the price agreed to do that by the IIs? They obviously the ones making the decisions here.
What did I say would happen last week! It's been walked down for Private Equity buyer! JMO
Funders are not going to keep giving £10-20mln a year to cash guzzling Co
They said this in December
Despite the ongoing challenges in the equity markets and broader economic landscape, post-period we were pleased to secure a £14.1 million (£13.6 million net) equity financing with existing institutional investors which extends our cash runway into Q3 2024 and will allow us to deliver multiple near-term value inflection points, in line with our refined strategic focus.
I been investing for a long time, but never had this happen. Just looked up what someone said about C4 and shares when down about 25% when they made identical announcement 5 days ago. But the IIs seem to want this to happen. So at some point they obviously think they are going to get much more than previous value for their shares??!!
I’m new to investing so what is going to happen to my shares now when they go private have l lost them all cheers
What they all have in common (SND C4XD REDX etc) is too much power to founders or IIs
This one Already has 84% acceptance
As at today's date, the Company has received letters of intent and irrevocable undertakings from certain Shareholders representing approximately 84.64 per cent. of the Company's issued share capital to vote in favour of the Resolutions.
AIM has lost it... a delisting getting very regular now especially in biotech...
It wouldn't surprise me if Private Equity took Redx of the AIM market seeing as AIM is currently being overlooked by investors. With a potential $870 million future payment ms from Jazz Pharma for Kras inhibitors, the current market cap appears very lowly and the Jazz partnership is definitely a thumbs up for Redx. I'll be sticking this one in the bottom draw as anything could happen here. JMO Adyor!
Article below is well worth a read. It explains the role of BTK inhibitors for the treatment of B cell cancers in a way that's easy to understand and why intolerance and resistance to treatment as well as side effects meant that more selective inhibitors were required.
The article then goes on to give a history of the development of Pirtobrutinib from its creation in Redx's labs through to acquisiton by Loxo and Lilly and FDA approval. It includes an interview with Nicholas Guisot, who heads up drug discovery at Redx and also Lilly's Jake Van Naarden who acknowledges that the drug was 'exceptionally difficult to deliver chemically'.
Good coverage for Redx highlighting its ability through highly complex chemistry to create best in class small molecules and make a real difference to patients' lives.
'Noncovalent BTK inhibitors like pirtobrutinib offer people with CLL a lifeline when covalent BTK inhibitors no longer work. “I’ve seen many patients that really benefited from that treatment option,” Abdel-Wahab says. What’s more, pirtobrutinib is taken as a pill at home and has few side effects. Before the drug was available, patients whose disease had become resistant to a covalent BTK inhibitor were left with treatments that had to be given as infusions and required an inpatient stay. “So it’s kind of a big deal,” he says'
https://cen.acs.org/pharmaceuticals/drug-development/battle-B-cell-cancers-drugmakers/102/i10
I believe the long term relationship with Jazz Pharma and recent KRAS agreement news is a significant positive for Redx. Working with multi-billion US based pharmaceutical Co is good for Redx shareholders, especially $10 million up front payment and potential $870 million future payments if all goes to plan with FDA etc.. JMO Adyor.
Code 1 printed for the believers. Tr1 coming up on seller. Good riddance
4 trades totalling 72 shares so far today, MM's must be short on supply side one assumes, unless no buyers out there?
It seems very few shares in circulation at the moment, maybe holders just sitting on hands for another positive update.
I think day to day moves we've had lately are mainly just down to low volumes. If there is a background seller, they can only be selling small amounts....
If you read through the Jazz results it mentions the Redx Pharma deals under heading Business Updates/Corporate Development
........."KRAS Inhibitor Program Agreement:
In February 2024, the Company acquired Redx Pharma's KRAS inhibitor program, which includes G12D selective and pan-KRAS molecules, further expanding Jazz's early-stage oncology pipeline.".......
GLA hopefully a good 2024 to come...
Jazz Pharma reported record sales of $3.8 billion for 2023 and over $1 billion in sales for Q4 2023, 27% growth year-on-year, seems a very good partner to have for Redx? Redx to be paid by Jazz and others for carrying out development work, so cash coming in to extend runway well into 2025 it seems? JMO Adyor!
https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2023
I meant $870 million deal..
https://www.lse.co.uk/rns/redx-announces-sale-of-kras-inhibitor-program-ppngbqoo8pjfuap.html
Upto $870 deal signed with Jazz Pharma a few weeks back yet SP going nowhere, seems quite strange reaction 🤔. Three previous cash raises at 56, 52 and recently 26p from institutional investors, so appetite for shares..one assumes its the lull in newsflow that's causing sp to drift?
Bobcat, if the seller is Polar again (not saying it is, but we might know soon if a TR-1 gets released) they seem to be dumping REDX and investing in RENX as they recently bought some newly issued shares with RENX. I think both companies are great opportunities but typically I've F'd up in my trades and have lost half my cash (and I mean actually lost as I sold too early and bought way to high on a stock. GLA.
MM's still playing around on low volume, wouldn't surprise me if they're lowering the bid to flush out weak holders?
Looks like seller still around. The earliest they sell up the better.